Maravai LifeSciences Announces Establishment of New Charitable Foundation
Maravai LifeSciences Foundation to support STEM, scientific education, community health, and COVID response
SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced it is establishing a new charitable foundation to promote causes tied to Maravai’s mission.
The Maravai LifeSciences Foundation anticipates focusing on charitable, scientific, and educational endeavors, with particular emphasis on advancing scientific education and innovation, supporting local communities in which we operate, promoting public health and access to healthcare, and advocating for inclusion and diversity.
In addition, the Foundation intends to establish a match for Maravai employee giving to help strengthen a broad range of nonprofit programs in communities where Maravai has a presence.
“Maravai is committed to being a strong corporate citizen, and the new Maravai Foundation will allow us to make an even bigger impact in our communities,” said Carl Hull, Maravai’s Chief Executive Officer. “We believe giving our time, money, and talent can make a positive impact on our surrounding communities.”
The Foundation is applying to the U.S. Internal Revenue Service for designation as tax exempt under Section 501(c)(3) of the Internal Revenue Code. Maravai expects that the Foundation will commence operations once 501(c)(3) status is approved and anticipates providing further information about the Foundation’s activities at that time.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologic safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit www.maravai.com.
Forward-looking Statements
This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the foundation’s areas of focus, the impact the foundation will have on communities, its intent to match employee contributions, and the foundation’s plans to apply for 501(c)(3) tax-exempt status from the Internal Revenue Service, constitute forward-looking statements identified by words like “expect,” “may,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation and uncertainties related to continued validation of the safety and effectiveness of our technology, new scientific developments, and competition from other products. These and other risks and uncertainties are described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
Contact Information: Media Contact: Sara Michelmore MacDougall Advisors +1 781-235-3060 maravai@macbiocom.com Investor Contact: Deb Hart Maravai LifeSciences +1 858-988-5917 ir@maravai.com
Released December 9, 2021